Imugene Launches First Australian Site for Azer-cel Phase 1b Trial in DLBCL.

Imugene Limited, a clinical-stage immuno-oncology company, has opened the first Australian site for its Phase 1b trial of azer-cel (azercabtagene zapreleucel) at the Royal Prince Alfred Hospital in Sydney. This trial, will start patient’s recruitment this month. Azer-cel is an off-the-shelf, allogeneic CAR T-cell therapy targeting the CD19 protein, offering quicker treatment and greater accessibility compared to traditional autologous CAR T therapies that require personalized cell processing.

Recent U.S. trial data showed promising outcomes, with three complete responses, including durable responses in patients from Cohort B treated with azer-cel, lymphodepletion chemotherapy, and interleukin-2. Imugene plans to expand to five sites in Australia to enhance patient access. This initiative represents a crucial advancement in offering novel treatment options for patients with few available choices.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com